Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

Does preventive oophorectomy increase the risk of depression in BRCA mutation carriers?

Kotsopoulos J, Gronwald J, Lubinski J, McCuaig J, Lynch HT, Neuhausen SL, Foulkes WD, Weitzel JN, Senter L, Tung N, Eng C, Karlan B, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group.

Menopause. 2019 Oct 21. doi: 10.1097/GME.0000000000001437. [Epub ahead of print]

PMID:
31644510
2.

A comparison of ovarian cancer mortality in women with BRCA1 mutations undergoing annual ultrasound screening or preventive oophorectomy.

Gronwald J, Lubinski J, Huzarski T, Cybulski C, Menkiszak J, Siołek M, Stawicka M, Sun P, Kim SJ, Kotsopoulos J, Narod SA.

Gynecol Oncol. 2019 Nov;155(2):270-274. doi: 10.1016/j.ygyno.2019.08.034. Epub 2019 Sep 26.

PMID:
31500890
3.

Menopausal hormones: definitive evidence for breast cancer.

Kotsopoulos J.

Lancet. 2019 Sep 28;394(10204):1116-1118. doi: 10.1016/S0140-6736(19)31901-4. Epub 2019 Aug 29. No abstract available.

4.

Changes in Bone Mineral Density After Prophylactic Bilateral Salpingo-Oophorectomy in Carriers of a BRCA Mutation.

Kotsopoulos J, Hall E, Finch A, Hu H, Murphy J, Rosen B, Narod SA, Cheung AM.

JAMA Netw Open. 2019 Aug 2;2(8):e198420. doi: 10.1001/jamanetworkopen.2019.8420.

5.

Blood arsenic levels and the risk of familial breast cancer in Poland.

Marciniak W, Derkacz R, Muszyńska M, Baszuk P, Gronwald J, Huzarski T, Cybulski C, Jakubowska A, Falco M, Dębniak T, Lener M, Oszurek O, Pullella K, Kotsopoulos J, Sun P, Narod SA, Lubiński J.

Int J Cancer. 2019 Jul 26. doi: 10.1002/ijc.32595. [Epub ahead of print]

PMID:
31348523
6.

Predictors of mammographic density among women with a strong family history of breast cancer.

Moran O, Eisen A, Demsky R, Blackmore K, Knight JA, Panchal S, Ginsburg O, Zbuk K, Yaffe M, Metcalfe KA, Narod SA, Kotsopoulos J.

BMC Cancer. 2019 Jun 26;19(1):631. doi: 10.1186/s12885-019-5855-2.

7.

Association between genetically predicted polycystic ovary syndrome and ovarian cancer: a Mendelian randomization study.

Harris HR, Cushing-Haugen KL, Webb PM, Nagle CM, Jordan SJ; Australian Ovarian Cancer Study Group, Risch HA, Rossing MA, Doherty JA, Goodman MT, Modugno F, Ness RB, Moysich KB, Kjær SK, Høgdall E, Jensen A, Schildkraut JM, Berchuck A, Cramer DW, Bandera EV, Rodriguez L, Wentzensen N, Kotsopoulos J, Narod SA, McLaughlin JR, Anton-Culver H, Ziogas A, Pearce CL, Wu AH, Lindström S, Terry KL.

Int J Epidemiol. 2019 Jun 1;48(3):822-830. doi: 10.1093/ije/dyz113.

PMID:
31211375
8.

Plasma RANKL levels are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.

Zaman T, Sun P, Narod SA, Salmena L, Kotsopoulos J.

Oncotarget. 2019 Mar 29;10(25):2475-2483. doi: 10.18632/oncotarget.26810. eCollection 2019 Mar 29.

9.

Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers.

Kotsopoulos J, Lubinski J, Lynch HT, Tung N, Armel S, Senter L, Singer CF, Fruscio R, Couch F, Weitzel JN, Karlan B, Foulkes WD, Moller P, Eisen A, Ainsworth P, Neuhausen SL, Olopade O, Sun P, Gronwald J, Narod SA; Hereditary Breast Cancer Clinical Study Group.

Breast Cancer Res Treat. 2019 Jun;175(2):443-449. doi: 10.1007/s10549-019-05162-7. Epub 2019 Feb 12.

PMID:
30756284
10.

Age-specific risks of incident, contralateral and ipsilateral breast cancer among 1776 Polish BRCA1 mutation carriers.

Lubinski J, Huzarski T, Gronwald J, Cybulski C, Debniak T, Sun P, Kim SJ, Kotsopoulos J, Narod SA.

Breast Cancer Res Treat. 2019 Apr;174(3):769-774. doi: 10.1007/s10549-018-05076-w. Epub 2019 Jan 5.

PMID:
30612273
11.

Folic acid supplement use and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a case-control study.

Kim SJ, Zhang CXW, Demsky R, Armel S, Kim YI, Narod SA, Kotsopoulos J.

Breast Cancer Res Treat. 2019 Apr;174(3):741-748. doi: 10.1007/s10549-018-05118-3. Epub 2019 Jan 2.

PMID:
30603998
12.

BRCA Mutations and Breast Cancer Prevention.

Kotsopoulos J.

Cancers (Basel). 2018 Dec 19;10(12). pii: E524. doi: 10.3390/cancers10120524. Review.

13.

Denosumab and breast cancer risk in postmenopausal women: a population-based cohort study.

Giannakeas V, Cadarette SM, Ban JK, Lipscombe L, Narod SA, Kotsopoulos J.

Br J Cancer. 2018 Nov;119(11):1421-1427. doi: 10.1038/s41416-018-0225-4. Epub 2018 Nov 13.

14.

Effects of bilateral salpingo-oophorectomy on menopausal symptoms and sexual functioning among women with a BRCA1 or BRCA2 mutation.

Hall E, Finch A, Jacobson M, Rosen B, Metcalfe K, Sun P, Narod SA, Kotsopoulos J.

Gynecol Oncol. 2019 Jan;152(1):145-150. doi: 10.1016/j.ygyno.2018.10.040. Epub 2018 Nov 7.

PMID:
30414741
15.

Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation.

Kotsopoulos J, Gronwald J, Karlan B, Rosen B, Huzarski T, Moller P, Lynch HT, Singer CF, Senter L, Neuhausen SL, Tung N, Eisen A, Foulkes WD, Ainsworth P, Sun P, Lubinski J, Narod SA; Hereditary Ovarian Cancer Clinical Study Group.

Gynecol Oncol. 2018 Jul;150(1):85-91. doi: 10.1016/j.ygyno.2018.05.011. Epub 2018 May 21.

PMID:
29793803
16.

Age at first full-term birth and breast cancer risk in BRCA1 and BRCA2 mutation carriers.

Kotsopoulos J, Gronwald J, Lynch HT, Eisen A, Neuhausen SL, Tung N, Ainsworth P, Weitzel JN, Pal T, Foulkes WD, Eng C, Singer CF, Senter L, Sun P, Lubinski J, Narod SA; Hereditary Breast Cancer Clinical Study Group.

Breast Cancer Res Treat. 2018 Sep;171(2):421-426. doi: 10.1007/s10549-018-4822-y. Epub 2018 May 17.

PMID:
29774471
17.

Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers.

Kotsopoulos J, Gronwald J, Karlan BY, Huzarski T, Tung N, Moller P, Armel S, Lynch HT, Senter L, Eisen A, Singer CF, Foulkes WD, Jacobson MR, Sun P, Lubinski J, Narod SA; Hereditary Breast Cancer Clinical Study Group.

JAMA Oncol. 2018 Aug 1;4(8):1059-1065. doi: 10.1001/jamaoncol.2018.0211. Erratum in: JAMA Oncol. 2018 Aug 1;4(8):1139.

18.

Serum osteoprotegerin levels and mammographic density among high-risk women.

Moran O, Zaman T, Eisen A, Demsky R, Blackmore K, Knight JA, Elser C, Ginsburg O, Zbuk K, Yaffe M, Narod SA, Salmena L, Kotsopoulos J.

Cancer Causes Control. 2018 Jun;29(6):507-517. doi: 10.1007/s10552-018-1035-y. Epub 2018 Apr 20.

PMID:
29679262
19.

Prospective evaluation of body size and breast cancer risk among BRCA1 and BRCA2 mutation carriers.

Kim SJ, Huzarski T, Gronwald J, Singer CF, Møller P, Lynch HT, Armel S, Karlan BY, Foulkes WD, Neuhausen SL, Senter L, Eisen A, Eng C, Panchal S, Pal T, Olopade O, Zakalik D, Lubinski J, Narod SA, Kotsopoulos J; Hereditary Breast Cancer Clinical Study Group.

Int J Epidemiol. 2018 Mar 13. doi: 10.1093/ije/dyy039. [Epub ahead of print]

20.

Correction: Serum selenium levels and the risk of progression of laryngeal cancer.

Lubiński J, Marciniak W, Muszynska M, Jaworowska E, Sulikowski M, Jakubowska A, Kaczmarek K, Sukiennicki G, Falco M, Baszuk P, Mojsiewicz M, Kotsopoulos J, Sun P, Narod SA, Lubiński JA.

PLoS One. 2018 Mar 12;13(3):e0194469. doi: 10.1371/journal.pone.0194469. eCollection 2018.

21.

Physical activity during adolescence and young adulthood and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

Lammert J, Lubinski J, Gronwald J, Huzarski T, Armel S, Eisen A, Meschino WS, Lynch HT, Snyder C, Eng C, Olopade OI, Ginsburg O, Foulkes WD, Elser C, Cohen SA, Kiechle M, Narod SA, Kotsopoulos J.

Breast Cancer Res Treat. 2018 Jun;169(3):561-571. doi: 10.1007/s10549-018-4694-1. Epub 2018 Feb 5.

PMID:
29404807
22.

The association between smoking and cancer incidence in BRCA1 and BRCA2 mutation carriers.

Ko KP, Kim SJ, Huzarski T, Gronwald J, Lubinski J, Lynch HT, Armel S, Park SK, Karlan B, Singer CF, Neuhausen SL, Narod SA, Kotsopoulos J; Hereditary Breast Cancer Clinical Study Group.

Int J Cancer. 2018 Jun 1;142(11):2263-2272. doi: 10.1002/ijc.31257. Epub 2018 Jan 25.

23.

Prophylactic mastectomy for BRCA mutation carriers after ovarian cancer treatment: is it beneficial?

Kotsopoulos J, Narod SA.

Expert Rev Anticancer Ther. 2018 Mar;18(3):199-200. doi: 10.1080/14737140.2018.1424547. Epub 2018 Jan 8. No abstract available.

PMID:
29308680
24.

Serum selenium levels and the risk of progression of laryngeal cancer.

Lubiński J, Marciniak W, Muszynska M, Jaworowska E, Sulikowski M, Jakubowska A, Kaczmarek K, Sukiennicki G, Falco M, Baszuk P, Mojsiewicz M, Kotsopoulos J, Sun P, Narod SA, Lubiński JA.

PLoS One. 2018 Jan 5;13(1):e0184873. doi: 10.1371/journal.pone.0184873. eCollection 2018. Erratum in: PLoS One. 2018 Mar 12;13(3):e0194469.

25.

BRCA Mutation Status Is Not Associated With Increased Hematologic Toxicity Among Patients Undergoing Platinum-Based Chemotherapy for Ovarian Cancer.

Kotsopoulos J, Willows K, Trat S, Kim RH, Volenik A, Sun P, Narod SA, Boyd J, May T.

Int J Gynecol Cancer. 2018 Jan;28(1):69-76. doi: 10.1097/IGC.0000000000001144.

PMID:
29194191
26.

Polycystic Ovary Syndrome, Oligomenorrhea, and Risk of Ovarian Cancer Histotypes: Evidence from the Ovarian Cancer Association Consortium.

Harris HR, Babic A, Webb PM, Nagle CM, Jordan SJ, Risch HA, Rossing MA, Doherty JA, Goodman MT, Modugno F, Ness RB, Moysich KB, Kjær SK, Høgdall E, Jensen A, Schildkraut JM, Berchuck A, Cramer DW, Bandera EV, Wentzensen N, Kotsopoulos J, Narod SA, Phelan CM, McLaughlin JR, Anton-Culver H, Ziogas A, Pearce CL, Wu AH, Terry KL; Ovarian Cancer Association Consortium; Australian Ovarian Cancer Study Group.

Cancer Epidemiol Biomarkers Prev. 2018 Feb;27(2):174-182. doi: 10.1158/1055-9965.EPI-17-0655. Epub 2017 Nov 15.

27.

Serum selenium levels predict survival after breast cancer.

Lubinski J, Marciniak W, Muszynska M, Huzarski T, Gronwald J, Cybulski C, Jakubowska A, Debniak T, Falco M, Kladny J, Kotsopoulos J, Sun P, Narod SA.

Breast Cancer Res Treat. 2018 Jan;167(2):591-598. doi: 10.1007/s10549-017-4525-9. Epub 2017 Oct 17.

PMID:
29043463
28.

Retraction: Circulating plant miRNAs can regulate human gene expression in vitro.

Pastrello C, Tsay M, McQuaid R, Abovsky M, Pasini E, Shirdel E, Angeli M, Tokar T, Jamnik J, Kotlyar M, Jurisicova A, Kotsopoulos J, El-Sohemy A, Jurisica I.

Sci Rep. 2017 May 22;7:46826. doi: 10.1038/srep46826.

29.

A Comparison of Survival Outcomes in Advanced Serous Ovarian Cancer Patients Treated With Primary Debulking Surgery Versus Neoadjuvant Chemotherapy.

May T, Comeau R, Sun P, Kotsopoulos J, Narod SA, Rosen B, Ghatage P.

Int J Gynecol Cancer. 2017 May;27(4):668-674. doi: 10.1097/IGC.0000000000000946.

PMID:
30814177
30.

A Comparison of Survival Outcomes in Advanced Serous Ovarian Cancer Patients Treated With Primary Debulking Surgery Versus Neoadjuvant Chemotherapy.

May T, Comeau R, Sun P, Kotsopoulos J, Narod SA, Rosen B, Ghatage P.

Int J Gynecol Cancer. 2017 May;27(4):668-674. doi: 10.1097/IGC.0000000000000946.

PMID:
28441250
31.

Response.

Kotsopoulos J, Sun P, Narod S.

J Natl Cancer Inst. 2017 Oct 1;109(10). doi: 10.1093/jnci/djx039. No abstract available.

PMID:
28383664
32.

Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted?

McGee J, Giannakeas V, Karlan B, Lubinski J, Gronwald J, Rosen B, McLaughlin J, Risch H, Sun P, Foulkes WD, Neuhausen SL, Kotsopoulos J, Narod SA; Hereditary Ovarian Cancer Clinical Study Group.

Gynecol Oncol. 2017 May;145(2):346-351. doi: 10.1016/j.ygyno.2017.02.032. Epub 2017 Mar 14.

PMID:
28314588
33.

Epidemiologic factors that predict long-term survival following a diagnosis of epithelial ovarian cancer.

Kim SJ, Rosen B, Fan I, Ivanova A, McLaughlin JR, Risch H, Narod SA, Kotsopoulos J.

Br J Cancer. 2017 Mar 28;116(7):964-971. doi: 10.1038/bjc.2017.35. Epub 2017 Feb 16.

34.

A Matched Case-Control Study of Risk Factors for Breast Cancer Risk in Vietnam.

Nguyen J, Le QH, Duong BH, Sun P, Pham HT, Ta VT, Kotsopoulos J, Narod SA, Ginsburg O.

Int J Breast Cancer. 2016;2016:7164623. doi: 10.1155/2016/7164623. Epub 2016 Dec 13.

35.

Plasma osteoprotegerin and breast cancer risk in BRCA1 and BRCA2 mutation carriers.

Odén L, Akbari M, Zaman T, Singer CF, Sun P, Narod SA, Salmena L, Kotsopoulos J.

Oncotarget. 2016 Dec 27;7(52):86687-86694. doi: 10.18632/oncotarget.13417.

36.

Revisiting breast cancer patients who previously tested negative for BRCA mutations using a 12-gene panel.

Moran O, Nikitina D, Royer R, Poll A, Metcalfe K, Narod SA, Akbari MR, Kotsopoulos J.

Breast Cancer Res Treat. 2017 Jan;161(1):135-142. doi: 10.1007/s10549-016-4038-y. Epub 2016 Oct 31.

PMID:
27798748
37.

Can we prevent BRCA1-associated breast cancer by RANKL inhibition?

Kotsopoulos J, Singer C, Narod SA.

Breast Cancer Res Treat. 2017 Jan;161(1):11-16. doi: 10.1007/s10549-016-4029-z. Epub 2016 Oct 25. Review.

PMID:
27783278
38.

Frequency of germline PALB2 mutations among women with epithelial ovarian cancer.

Kotsopoulos J, Sopik V, Rosen B, Fan I, McLaughlin JR, Risch H, Sun P, Narod SA, Akbari MR.

Fam Cancer. 2017 Jan;16(1):29-34. doi: 10.1007/s10689-016-9919-z.

PMID:
27631815
39.

Circulating plant miRNAs can regulate human gene expression in vitro.

Pastrello C, Tsay M, McQuaid R, Abovsky M, Pasini E, Shirdel E, Angeli M, Tokar T, Jamnik J, Kotlyar M, Jurisicova A, Kotsopoulos J, El-Sohemy A, Jurisica I.

Sci Rep. 2016 Sep 8;6:32773. doi: 10.1038/srep32773. Retraction in: Sci Rep. 2017 May 22;7:46826.

40.

Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.

Kotsopoulos J, Huzarski T, Gronwald J, Singer CF, Moller P, Lynch HT, Armel S, Karlan B, Foulkes WD, Neuhausen SL, Senter L, Tung N, Weitzel JN, Eisen A, Metcalfe K, Eng C, Pal T, Evans G, Sun P, Lubinski J, Narod SA; Hereditary Breast Cancer Clinical Study Group.

J Natl Cancer Inst. 2016 Sep 6;109(1). doi: 10.1093/jnci/djw177. Print 2017 Jan.

41.

Reduced BRCA1 transcript levels in freshly isolated blood leukocytes from BRCA1 mutation carriers is mutation specific.

Chehade R, Pettapiece-Phillips R, Salmena L, Kotlyar M, Jurisica I, Narod SA, Akbari MR, Kotsopoulos J.

Breast Cancer Res. 2016 Aug 17;18(1):87. doi: 10.1186/s13058-016-0739-8.

42.

Plasma folate, vitamin B-6, and vitamin B-12 and breast cancer risk in BRCA1- and BRCA2-mutation carriers: a prospective study.

Kim SJ, Zuchniak A, Sohn KJ, Lubinski J, Demsky R, Eisen A, Akbari MR, Kim YI, Narod SA, Kotsopoulos J.

Am J Clin Nutr. 2016 Sep;104(3):671-7. doi: 10.3945/ajcn.116.133470. Epub 2016 Jul 27.

PMID:
27465373
43.

Breast cancer survival among young women: a review of the role of modifiable lifestyle factors.

Brenner DR, Brockton NT, Kotsopoulos J, Cotterchio M, Boucher BA, Courneya KS, Knight JA, Olivotto IA, Quan ML, Friedenreich CM.

Cancer Causes Control. 2016 Apr;27(4):459-72. doi: 10.1007/s10552-016-0726-5. Epub 2016 Mar 12. Review.

44.

Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case-control study.

Kotsopoulos J, Huzarski T, Gronwald J, Moller P, Lynch HT, Neuhausen SL, Senter L, Demsky R, Foulkes WD, Eng C, Karlan B, Tung N, Singer CF, Sun P, Lubinski J, Narod SA.

Breast Cancer Res Treat. 2016 Jan;155(2):365-73. doi: 10.1007/s10549-016-3685-3. Epub 2016 Jan 16.

PMID:
26780555
45.

Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation.

Gronwald J, Glass K, Rosen B, Karlan B, Tung N, Neuhausen SL, Moller P, Ainsworth P, Sun P, Narod SA, Lubinski J, Kotsopoulos J; Hereditary Breast Cancer Clinical Study Group.

Fertil Steril. 2016 Mar;105(3):781-785. doi: 10.1016/j.fertnstert.2015.11.034. Epub 2015 Dec 14.

PMID:
26698676
46.

Relationship between Caffeine and Levels of DNA Repair and Oxidative Stress in Women with and without a BRCA1 Mutation.

Nikitina D, Chen Z, Vallis K, Poll A, Ainsworth P, Narod SA, Kotsopoulos J.

J Nutrigenet Nutrigenomics. 2015;8(4-6):174-84. doi: 10.1159/000439110. Epub 2015 Dec 16.

PMID:
26670362
47.

Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status.

Kotsopoulos J, Rosen B, Fan I, Moody J, McLaughlin JR, Risch H, May T, Sun P, Narod SA.

Gynecol Oncol. 2016 Jan;140(1):42-7. doi: 10.1016/j.ygyno.2015.11.009. Epub 2015 Nov 7.

PMID:
26556769
48.

Uninterrupted Sedentary Behavior Downregulates BRCA1 Gene Expression.

Pettapiece-Phillips R, Kotlyar M, Chehade R, Salmena L, Narod SA, Akbari M, Jurisica I, Kotsopoulos J.

Cancer Prev Res (Phila). 2016 Jan;9(1):83-8. doi: 10.1158/1940-6207.CAPR-15-0291. Epub 2015 Nov 2.

49.

Weight gain after oophorectomy among women with a BRCA1 or BRCA2 mutation.

Kotsopoulos J, Lubinski J, Neuhausen SL, Gronwald J, Lynch HT, Huzarski T, Demsky R, Foulkes WD, Senter L, Friedman S, Ainsworth P, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group.

Womens Health (Lond). 2015 Jul;11(4):453-9. doi: 10.2217/WHE.15.4. Epub 2015 Aug 10.

PMID:
26258912
50.

Risk Factors for Premenopausal Breast Cancer in Bangladesh.

Iqbal J, Ferdousy T, Dipi R, Salim R, Wu W, Narod SA, Kotsopoulos J, Mostafa MG, Ginsburg O.

Int J Breast Cancer. 2015;2015:612042. doi: 10.1155/2015/612042. Epub 2015 Jul 1.

Supplemental Content

Loading ...
Support Center